Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model

Talazoparib, a potent PARP inhibitor, induces synthetic lethality in BRCA-deficient cancers making it an attractive candidate for ovarian cancer treatment. However, its potency lends itself to side effects associated more closely with traditional chemotherapeutics than other clinically approved PARP...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Paige Baldwin, Anders W. Ohman, Jamie E. Medina, Eric T. McCarthy, Daniela M. Dinulescu, Srinivas Sridhar
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2019-05-01
סדרה:	Frontiers in Oncology
נושאים:	talazoparib intraperitoneal therapy nanoparticle ovarian cancer PARP inhibitor
גישה מקוונת:	https://www.frontiersin.org/article/10.3389/fonc.2019.00353/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!